- Home
- CING vs LSTA Comparison
CING vs LSTA Comparison
Compare CING & LSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CING
- LSTA
- Stock Information
- Founded
- CING 2012
- LSTA 1980
- Country
- CING United States
- LSTA United States
- Employees
- CING N/A
- LSTA N/A
- Industry
- CING Biotechnology: Pharmaceutical Preparations
- LSTA Misc Health and Biotechnology Services
- Sector
- CING Health Care
- LSTA Health Care
- Exchange
- CING Nasdaq
- LSTA Nasdaq
- Market Cap
- CING 22.9M
- LSTA 20.9M
- IPO Year
- CING 2021
- LSTA N/A
- Fundamental
- Price
- CING N/A
- LSTA $2.53
- Analyst Decision
- CING Strong Buy
- LSTA Strong Buy
- Analyst Count
- CING 4
- LSTA 2
- Target Price
- CING $31.00
- LSTA $23.50
- AVG Volume (30 Days)
- CING 160.4K
- LSTA 32.8K
- Earning Date
- CING 11-06-2025
- LSTA 11-11-2025
- Dividend Yield
- CING N/A
- LSTA N/A
- EPS Growth
- CING N/A
- LSTA N/A
- EPS
- CING N/A
- LSTA N/A
- Revenue
- CING N/A
- LSTA $1,070,000.00
- Revenue This Year
- CING N/A
- LSTA N/A
- Revenue Next Year
- CING N/A
- LSTA N/A
- P/E Ratio
- CING N/A
- LSTA N/A
- Revenue Growth
- CING N/A
- LSTA N/A
- 52 Week Low
- CING $3.02
- LSTA $1.87
- 52 Week High
- CING $6.01
- LSTA $4.20
- Technical
- Relative Strength Index (RSI)
- CING 53.04
- LSTA 54.11
- Support Level
- CING $3.91
- LSTA $2.36
- Resistance Level
- CING $4.24
- LSTA $2.62
- Average True Range (ATR)
- CING 0.21
- LSTA 0.19
- MACD
- CING 0.06
- LSTA 0.02
- Stochastic Oscillator
- CING 79.18
- LSTA 71.70
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic area to use PTR technology to develop future product candidates.
About LSTA Lisata Therapeutics Inc.
Lisata Therapeutics Inc is a clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product, certepetide, is designed to activate a novel uptake pathway that allows co-administered or tethered (i.e., molecularly bound) anti-cancer drugs to target and penetrate solid tumors more effectively. The group has one operating segment, the research and development of its investigational drug product.